Term ended Feb 18, 2024 · Medium confidence
20-year base term ended Feb 18, 2024
Why Medium: A parent in the chain could not be resolved.
USPTO later recorded it as expired for non-payment on Jul 20, 2026.
Feb 18, 2004
Feb 18, 2024
Jun 17, 2014
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 18, 2004, when application PCT/US2004/004646, the earliest non-provisional in its chain, was filed (this one was filed Aug 27, 2013); a parent in its chain could not be resolved (the next row) | Feb 18, 2024 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,767,851, US 8,338,642) | resolves to Feb 18, 2024, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | term ended | High confidence |
| USPTO status record | Recorded as expired for non-payment on Jul 20, 2026, after the term ended | no change | High confidence |
| Computed term end | The steps above, in order | Feb 18, 2024 | Medium confidence |
This family
| Application PCT/US2004/004646 | PCT application no patent term | no patent term |
| US 7,767,851 | Term ended Feb 2024 | Feb 2024 |
| US 8,093,423 | In force Oct 2028 | Oct 2028 |
| US 8,338,642 | Term ended Feb 2024 | Feb 2024 |
| US 8,299,298 | Term ended Feb 2024 | Feb 2024 |
| US 8,754,257 | Term ended Feb 2024 | Feb 2024 |
| US 8,609,896 | Term ended Feb 2024 | Feb 2024 |
| US 8,754,258 | this patent Feb 2024 | Feb 2024 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 6, 2014 Reel 32164, frame 131 | Kwok, David W.k.; Stoynov, Nikolay Mintchev | Panion & BF Biotech Inc. | Assignment of Assignor's Interest |
| Feb 6, 2014 Reel 32163, frame 938 | Panion & BF Biotech Inc. | Globoasia LLC | Assignment of Assignor's Interest |
| Feb 6, 2014 Reel 32164, frame 212 | Globoasia LLC | Panion & BF Biotech Inc. | Nunc Pro Tunc Assignment |
| Apr 2, 2020 Reel 52295, frame 662 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Security Interest |
| Sep 2, 2020 Reel 53671, frame 221 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Second Amended and Restated Intellectual Property Security Agreement |
| Sep 10, 2020 Reel 54173, frame 451 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Third Amended and Restated Intellectual Property Security Agreement |
| Dec 17, 2020 Reel 54793, frame 455 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fourth Amended and Restated Intellectual Property Security Agreement |
| Mar 30, 2021 Reel 55776, frame 491 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fifth Amended and Restated Intellectual Property Security Agreement |
| Jun 11, 2021 Reel 56544, frame 468 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Sixth Amended and Restated Intellectual Property Security Agreement |
| Sep 12, 2021 Reel 57474, frame 770 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Seventh Amended and Restated Intellectual Property Security Agreement |
| Dec 15, 2021 Reel 58399, frame 55 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Security Interest |
| Jun 16, 2022 Reel 60529, frame 168 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Tenth Amended and Restated Intellectual Property Security Agreement |
| Aug 22, 2022 Reel 61297, frame 238 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Eleventh Amended and Restated Intellectual Property Security Agreement |
| Nov 29, 2022 Reel 62012, frame 561 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Twelfth Amended and Restated Intellectual Property Security Agreement |
| Mar 29, 2023 Reel 63189, frame 65 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Thirteenth Amended and Restated Intellectual Property Security Agreement |
| Jan 4, 2024 Reel 66205, frame 143 | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Biopharma Credit PLC | Fifteenth Amended and Restated Intellectual Property Security Agreement |
| Jan 29, 2024 Reel 66377, frame 741 | Biopharma Credit PLC | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jan 29, 2024 reel/frame not recorded | Biopharma Credit PLC | Akebia Therapeutics, Inc. | Termination and Release of Security Interest in Patents |
| Jan 29, 2024 reel/frame not recorded | Biopharma Credit PLC | Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 Reel 67839, frame 134 | Biopharma Credit PLC | Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 reel/frame not recorded | Biopharma Credit PLC | Akebia Therapeutics, Inc. | Termination and Release of Security Interest in Patents |
| Jun 25, 2024 reel/frame not recorded | Biopharma Credit PLC | Keryx Biopharmaceuticals, Inc. | Termination and Release of Security Interest in Patents |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
A terminal disclaimer resolved from the filed document, referencing US 7,767,851, US 8,338,642, ends no earlier than this term, so it caps nothing.